Morishima S, Suzuki F, Yoshiki H, Md Anisuzzaman A S, Sathi Z S, Tanaka T, Muramatsu I
Division of Pharmacology, Department of Biochemistry and Bioinformative Sciences, School of Medicine, University of Fukui, Eiheiji, Fukui, Japan.
Br J Pharmacol. 2008 Apr;153(7):1485-94. doi: 10.1038/sj.bjp.0707679. Epub 2008 Jan 28.
In addition to alpha1A, alpha1B and alpha1D-adrenoceptors (ARs), putative alpha1L-ARs with a low affinity for prazosin have been proposed. The purpose of the present study was to identify the alpha1A-AR and clarify its pharmacological profile using a radioligand binding assay.
Binding experiments with [3H]-silodosin and [3H]-prazosin were performed in intact tissue segments and crude membrane preparations of rat cerebral cortex. Intact tissue binding assays were also conducted in rat tail artery.
[3H]-silodosin at subnanomolar concentrations specifically bound to intact tissue segments and membrane preparations of rat cerebral cortex at the same density (approximately 150 fmol mg(-1) total tissue protein). The binding sites in intact segments consisted of alpha1A and alpha1L-ARs that had different affinities for prazosin, while the binding sites in membranes showed an alpha1A-AR-like profile having single high affinity for prazosin. [3H]-prazosin also bound at subnanomolar concentrations to alpha1A and alpha1B-ARs but not alpha1L-ARs in cerebral cortex; the binding densities being approximately 200 and 290 fmol mg(-1) protein in the segments and the membranes, respectively. In the segments of tail artery, [3H]-silodosin only recognized alpha1A-ARs, whereas [3H]-prazosin bound to alpha1A and alpha1B-ARs.
The present study clearly reveals the presence of alpha1L-ARs as a pharmacologically distinct entity from alpha1A and alpha1B-ARs in intact tissue segments of rat cerebral cortex but not tail artery. However, the alpha1L-ARs disappeared after tissue homogenization, suggesting their decomposition and/or their pharmacological profile changes to that of alpha1A-ARs.
除α1A、α1B和α1D肾上腺素能受体(ARs)外,还提出了对哌唑嗪亲和力低的假定α1L-ARs。本研究的目的是利用放射性配体结合试验鉴定α1A-AR并阐明其药理学特征。
在大鼠大脑皮层的完整组织切片和粗制膜制剂中进行了用[3H]-西洛多辛和[3H]-哌唑嗪的结合实验。也在大鼠尾动脉中进行了完整组织结合试验。
亚纳摩尔浓度的[3H]-西洛多辛以相同密度(约150 fmol mg(-1)总组织蛋白)特异性结合于大鼠大脑皮层的完整组织切片和膜制剂。完整切片中的结合位点由对哌唑嗪具有不同亲和力的α1A和α1L-ARs组成,而膜中的结合位点显示出对哌唑嗪具有单一高亲和力的α1A-AR样特征。[3H]-哌唑嗪在亚纳摩尔浓度下也结合于大脑皮层中的α1A和α1B-ARs,但不结合α1L-ARs;在切片和膜中的结合密度分别约为200和290 fmol mg(-1)蛋白。在尾动脉切片中,[3H]-西洛多辛仅识别α1A-ARs,而[3H]-哌唑嗪结合于α1A和α1B-ARs。
本研究清楚地揭示了在大鼠大脑皮层而非尾动脉的完整组织切片中,α1L-ARs作为一种药理学上与α1A和α1B-ARs不同的实体存在。然而,α1L-ARs在组织匀浆后消失,表明它们分解和/或其药理学特征转变为α1A-ARs的特征。